CWM
KPTI icon

Catamount Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Catamount Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1K Hold
17
– – ﹤0.01% 184
2018
Q4 		$2K Hold
17
– – ﹤0.01% 188
2018
Q3 		$4K Buy
+17
New +$4.7K ﹤0.01% 170

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Catamount Wealth Management's KPTI Position: Q1 2019 in Review

Catamount Wealth Management held its Karyopharm Therapeutics (KPTI) position steady in Q1 2019 at 17 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #184.

Catamount Wealth Management first reported a position in KPTI in Q3 2018 and has held it in 3 quarters since. The position peaked at $4K in Q3 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • Catamount Wealth Management held 17 shares of Karyopharm Therapeutics worth $1K as of Q1 2019.
  • Catamount Wealth Management left its Karyopharm Therapeutics share count unchanged in Q1 2019.
  • Karyopharm Therapeutics made up ﹤0.01% of Catamount Wealth Management's portfolio in Q1 2019, its #184 holding.
  • Catamount Wealth Management first reported a position in Karyopharm Therapeutics in Q3 2018 and has held it in 3 quarters since.
  • Catamount Wealth Management's Karyopharm Therapeutics position peaked at $4K in Q3 2018.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on Catamount Wealth Management's 13F filing for Q1 2019, filed 3 May 2019.